Clinically relevant interactions between newer antidepressants and second-generation antipsychotics (Q38185057)

30 August 2017

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Jose de Leon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

5 February 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

721-746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24494611%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Schizoaffective disorder: a review of current research themes and pharmacological management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antidepressants: clinically relevant drug interactions to be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Clinically significant drug interactions with newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Metabolic drug interactions with newer antipsychotics: a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Clinically significant drug interactions with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Iloperidone, asenapine and lurasidone: a primer on their current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Transporter-mediated drug interactions: clinical implications and in vitro assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Relationship between P-glycoprotein and second-generation antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Psychotropic drug-drug interactions involving P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Vortioxetine: first global approval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Interactions between antiepileptics and second-generation antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Influence of fluoxetine on olanzapine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Extrapyramidal symptoms after addition of fluvoxamine to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Interaction of olanzapine with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Plasma risperidone concentrations during combined treatment with sertraline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Challenges in the treatment of major depressive disorder with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Mania associated with antidepressant treatment: comprehensive meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Serotonin syndrome caused by ziprasidone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine -- case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Serotonin syndrome associated with clozapine withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Selective serotonin reuptake inhibitor-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Akathisia and second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

21 January 2018

Drug-induced arrhythmia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Drug-induced long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504

Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885504